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1. Introduction 
In this chapter we discuss the global epidemiology of hepatitis B virus (HBV) in the general 
population and compare the data with those from populations at higher risk for hepatitis B 
infection, as hemodialysis patients. We discuss disease burden, HBV genotype distribution, 
and patterns of HBV transmission in the general population and among hemodialysis 
patients. We focus on the importance of detecting occult HBV infection in hemodialysis. 
Finally, we compare HBV variants detected in the general population with those detected by 
nosocomial transmission in hemodialysis units.  
2. History of hepatitis B virus 
HBV is an etiologic agent of acute and chronic liver disease in humans. About one-third of 
people infected with HBV have a completely "silent" disease. When symptoms are present, 
they may be mild or severe. The most common early symptoms are mild fever, headache, 
muscle aches, fatigue, loss of appetite, nausea, vomiting and diarrhea. Later symptoms may 
include dark coffee-colored, rather than dark yellow, urine, clay-colored stools, abdominal 
pain, and yellowing of the skin and whites of the eyes (jaundice). Several reports of the 
occurrence of epidemic jaundice are found from the period before the Christian era, and 
were initially described by Hippocrates (400 BC). However, only in the late nineteenth 
century, after smallpox vaccination (vaccine prepared from human lymph) of 1,289 shipyard 
workers in Bremen, Germany, of which 15% became jaundiced, it became clear the 
association of this illness with an agent of parenteral transmission (Lurman, 1885). 
During the first half of the twentieth century, outbreaks of hepatitis of "long incubation 
period” (30-180 days) were observed in many countries and have been associated with 
blood transfusions, use of injectable drugs, unsterilized needles and syringes, and vaccine 
administration, for example, an outbreak of hepatitis/jaundice occurred in militaries who 
were vaccinated against yellow fever during the Second World War (Krugman, 1989). 
The 1940s was the period in which distinguished the presence of more than one viral agent 
for the epidemic of jaundice. In 1947, MacCallum appointed the terms “hepatitis A virus” 
(HAV) and “hepatitis B virus” (HBV), referring to the presumed etiologic agents of hepatitis 
of short incubation period (18 to 37 days) and long incubation period (30 to 180 days), 
respectively. This terminology was adopted by the committee of viral hepatitis of the World 
Health Organization, staying until nowadays (Hollinger, 1991). 
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In 1965, Blumberg and colleagues published what would become one of the most important 
revelations about viral hepatitis. With the aim of studying polymorphic hereditary 
characteristics, Blumberg and his team examined thousands of serum samples from 
different geographic areas of the world. During the course of the investigation, the team 
found that a serum sample from an Australian aborigine contained an antigen that reacted 
specifically with an antibody present in the serum of a hemophiliac patient in the United 
States. Subsequent studies revealed that this "Australia antigen" was relatively rare in the 
population of North America and Western Europe, but prevalent in some African and Asian 
regions and among patients with leukemia, Down syndrome and acute hepatitis (Bayer et 
al., 1968; Blumberg et al., 1967). In 1968, the correlation of the Australia antigen (now called 
the surface antigen of hepatitis B or HBsAg) with HBV, could be established 
(Okochi&Murakami, 1968; Prince, 1968). Subsequently, the purification of HBV was 
performed from serum of carriers of Australia antigen and the complete particle or virion 
was detected by electron microscopy (Dane et al., 1970). 
3. HBV routes of transmission 
HBV is present in high titers in blood and exudates of acutely and chronically infected 
persons. More moderate viral titers are found in semen, urine, saliva, and nasopharyngeal 
fluid (Alter et al., 1977; Davison et al., 1987). HBV is present in the blood of individuals 
positive for hepatitis B e antigen (HBeAg, a marker of high infectivity) at a concentration of 
approximately 108 to 109 viral particles per milliliter (mL) of blood (Dane et al., 1970). By 
comparison, human immunodeficiency virus (HIV) is present in blood at much lower 
concentrations: 103 to 104 viral particles/mL for a person with AIDS and 10 to 100/mL for a 
person with asymptomatic HIV infection (Ho et al., 1989). The risk of HBV transmission 
after percutaneous exposure to HBeAg-positive blood is approximately 100-fold higher than 
the risk of HIV transmission after percutaneous exposure to HIV infected blood (CDC, 
2011). In addition, HBV is an extremely resistant virus, capable of withstanding extreme 
temperature and humidity. HBV retains infectivity when stored at 30°C to 32°C for at least 6 
months and when frozen at –15°C for 15 years. HBV present in blood can resist drying on a 
surface for at least a week (Hollinger&Liang, 2001). These characteristics explain why HBV 
is so highly transmissible by a variety of percutaneous procedures, with an annual global 
estimation of 8–16 million new HBV infections due to the use of unsafe injections (Simonsen 
et al., 1999). 
HBV transmission occurs mainly by percutaneous or mucosal exposure to infected blood. It 
also occurs through perinatal exposure, sexual intercourse, exposure to blood products 
(needles shared by intravenous drug users, by skin lesions) and through organ 
transplantation. In areas of high incidence of HBV infection, dissemination occurs mainly in 
children, either at birth (perinatal) or during the first years of life by horizontal transmission 
among family members (Margolis et al., 1991). Perinatal transmission from mother to child 
may occur during birth by newborn exposure to blood or amniotic fluid. In areas of low 
prevalence, the infection occurs primarily in adults. Individuals at high risk for HBV 
infection are injecting drug users (Alter, 1993; Oliveira et al., 1999), homosexual or 
heterosexual individuals with multiple sexual partners (Piot et al., 1990), health 
professionals (Beltrami et al., 2000) and polytransfused patients. Patients undergoing 
hemodialysis are at high risk of acquiring HBV (Canero-Velasco et al., 1998; Covic et al., 
1999; Vladutiu et al., 2000).  
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4. Clinical features 
It is believed that the HBV itself does not exert a direct cytopathic effect on hepatocytes 
(Alberti et al., 1983). Hepatitis B infection can, however, vary from an acute self-limited to a 
severe form of fulminant hepatitis. The course of HBV infection can be extremely variable. It 
may be unapparent or patients may develop symptoms. Asymptomatic cases can be 
identified by detecting biochemical or virus specific serological alterations. Symptoms range 
from mild to severe. It is estimated that about 90-95% of infected adults will recover from 
the infection, and less than 1% of individuals may develop a fulminant hepatitis. However, 
children up to 5 years old, have over 90% of chance of becoming chronic carriers due to the 
immature immune system. Patients with acute hepatitis may recover completely or progress 
to chronic hepatitis. Acute hepatitis can be divided into four clinical phases (a) incubation 
period that usually ranges from 30 to 180 days; (b) pre-icteric phase, ranging from several 
days to more than a week. This phase is typically characterized by mild fever, fatigability, 
anorexia, nausea and vomiting. At this stage, patients may refer diffuse abdominal pain, 
intolerance to various foods, taste disturbances, abdominal discomfort. The occurrence of 
arthritis, arthralgia and myalgia are described as well as the observation rubelliform rashes 
(McIntyre, 1990). Physical examination may reveal a mild hepatomegaly; (c) icteric phase 
that is characterized by the appearance of dark, golden-brown urine, followed by pale stools 
and discoloration of the mucous membranes, conjunctivae, and skin. This icteric phase 
begins within 10 days of the initial symptoms in over 85% of the HBV cases and; (d) 
convalescent period. In this stage, with the evolution of the disease, painful hepatomegaly 
and splenomegaly, and any gastrointestinal symptoms and those related to jaundice, if 
present, will gradually diminish. This recovery period lasts on average 20 to 30 days.  
5. HBV open reading frames 
HBV represents the prototype of Hepadnaviridae family (genus Orthohepadnavirus) where a 
group of singular few viruses with genomes composed by a partial double stranded DNA 
replicating via reverse transcriptase were clustered. HBV is one of the smallest genomes of 
human viruses, with about 3.2 Kb. The HBV genome is fully coding with four open reading 
frames designated pre-S/S, pre-C/C, P and X. All the virus genes are overlapped at least to 
one other open reading frame, and due to this characteristic, HBV may produce about 50% 
more proteins than expected for the size of its genome (Ganem&Varmus, 1987). The 
genomic pre-S/S region encodes the viral surface proteins (HBsAg) that is abundant in 
serum of infected individual. The pre-C/C region is responsible for the synthesis of the 
proteins that form HBV capsid, named core antigen (HBcAg). This region also synthesizes 
the e antigen (HBeAg) that is secreted from HBV particles and is found free in the serum of 
infected individuals. HBeAg is an important marker of active replication. The open reading 
frame for the polymerase (P gene) encodes the viral polymerase with activity of reverse 
transcriptase, and RNAseH. This protein is the target of anti-HBV drugs (see Topic 9). A 
small gene named X synthesizes a regulatory protein, called protein X (HBxAg). Almost all 
HBV proteins and antibodies against these products are important markers for HBV 
serological detection. 
6. HBV serological and molecular markers of infection 
From a clinical point of view, viral hepatitis has very similar symptoms. The etiological 
diagnosis to identify the causative agent of infection can be performed by serological 
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techniques, immuno-histochemical and molecular research. Biochemical tests of liver 
function, such as determination of transaminases (alanine aminotransferase - ALT and 
aspartate aminotransferase - AST) and bilirubin are also performed for diagnostic purposes, 
because their serum levels increase during episodes of hepatocellular injury or necrosis due 
to viral infection (Sjogren, 1994). The symptoms start with the elevation of 
aminotransferases, and patients become positive to anti-HBc IgM. Anti-HBc IgM together 
with HBsAg, is the key to diagnosing acute infection, since the IgG fraction of this antibody 
serves only as evidence of immune memory. Despite being a long-lasting antibody, anti-HBc 
does not confer immunity to the individual, it does not have neutralizing capacity (Sjogren, 
1994). The early disease markers of virus replication (HBeAg and HBV-DNA) are found in 
high titers. As the infection sets in, the host immune response modulates the infection and 
progressively decreases viral replication. Individuals who present satisfactory immune 
response can resolve viral replication, usually within the first 3 months of illness, giving rise 
to anti-HBe antibody, which is associated with a poor replication of HBV. The absence of the 
seroconversion HBeAg/anti-HBe within the first 3 months of acute illness is a sign of poor 
prognosis, indicating failure of the immune system and tendency to chronicity of the 
process. Upon the termination of viral replication, HBsAg gradually disappears and, after a 
few weeks, anti-HBs emerges, thus, conferring immunity to the patient. Chronic hepatitis is 
determined by the persistence of HBsAg in serum for more than six months after the onset 
of infection. In chronic patients, markers of viral replication and clinical manifestations are 
dependent on the virus-host interactions (Sjogren, 1994).  
 
  
 
Fig. 1. Typical serologic course of acute and chronic HBV infections. Available in 
<http://www.cdc.gov/ncidod/diseases/hepatitis/slideset/hep_b/slide_3.htm> and 
<http://www.cdc.gov / ncidod/diseases/hepatitis/slideset/hep_b/slide_4 . htm> 
[Accessed on 16 Jan. 2008]. 
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Figure 1 shows the curves of serological markers in acute and chronic HBV infections. Table 
1 provides interpretations for hepatitis B serologic markers. 
 
 
Table 1. Interpretation of hepatitis B serologic test results. Available in 
<http://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf> [Accessed on 01 April 
2011]. 
7. Epidemiology of HBV 
According to the most recent data of World Health Organization (WHO, 2008), it is 
estimated that more than 2 billion people worldwide have been infected with HBV. Of 
these, approximately 360 million suffer from chronic HBV infection, resulting in over 
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600.000 deaths each year mainly from cirrhosis or liver cancer. The distribution of HBV 
infection is not uniform around the world. The world areas were classified into high, 
medium or low endemicity for HBV, depending on the prevalence of the HBV serological 
marker of active infection, the HBsAg. HBsAg is highly prevalent (8-15 %) in Southeast Asia, 
China, Philippines, Africa, the Amazon basin and the Middle East. An intermediate 
prevalence of HBsAg (2-7%) is observed in Eastern Europe, Central Asia, Japan, Israel and  
Russia, while a low prevalence (<2%) is found in North America, Western Europe, Australia 
and South America (CDC, 2011) (Figure 2). About 45% of HBV infected people are living in 
areas where HBsAg prevalence is 8% or higher, with a risk of infection of more than 60%, 
mostly during the childhood and with a high risk of chronicity. Forty-three percent of 
worldwide infected people are living in areas of intermediate prevalence with risk of 
infection of 20-60%, occurring across all age groups. Only the remaining 12% are living in 
areas of low prevalence with risk of infection of less than 20%, occurring mainly in 
adulthood (Te&Jensen, 2010). Despite the impressive number of HBV infected people, the 
worldwide incidence is in decreasing mostly due to the effort toward global prevention of 
hepatitis B by vaccination. Hepatitis B vaccine has been available since 1982 and at least 1 
billion people have been vaccinated worldwide. The efficacy of HBV vaccination in the 
prevention of HBV infection has been shown to be over 90% in most countries (de Franchis 
et al., 2003) and universal vaccination is regarded to be the key toward elimination and 
eradication of HBV (Chen, 2009). 
 
 
Fig. 2. Geographic distributions of hepatitis B infection worldwide, 2006. (Data from Central 
Disease Control, available from: 
http://www.cdc.gov/hepatitis/HBV/PDFs/HBV_figure3map_08-27-08.pdf 
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8. Prevention of hepatitis B 
The first HBV vaccine was licensed in 1981 and was derived from human plasma of chronic 
HBV (Heptavax-B, Merck & Co). However, the risk of transmission of other infectious 
agents present in the plasma, has stimulated the development of recombinant vaccines 
composed of HBsAg produced by genetic engineering (Engerix-B, Recombivax and 
SmithKline, Merck & Co). For the production of vaccines, recombinant DNA technology 
uses expression of HBsAg in yeast (Assad&Francis, 1999). The vaccine has good 
immunogenicity against HBV, approximately 90% of immunocompetent individuals 
vaccinated develop an adequate antibody response. Moreover, the vaccine has the potential 
to reduce the incidence of liver cancer (Blumberg, 1997). The scheme currently 
recommended to the recombinant vaccines is 3 doses intramuscularly in the deltoid muscle 
at intervals of one month (between 1st and 2nd dose) and 5 months (between 2nd and 3rd 
dose) - Schema 0, 1, 6 months (Assad&Francis, 1999). The protective efficacy of HBV vaccine 
is directly related to the level of anti-HBs produced and it is necessary for protection levels 
equal or greater than 10 mIU/ml (CDC, 1991). The immunoprophylaxis through the use of 
specific hyperimmune globulin (HBIG) is used to give immediate passive protection to 
individuals who have been recently exposed to HBV, for example, after an accidental 
puncture, sexual contact with a carrier or, during delivery of newborns of HBsAg positive 
mothers (Perrillo et al., 1984).  
9. Treatment of chronic hepatitis B infection 
The main goal of treatment for chronic hepatitis B is to suppress viral replication and 
reducing liver damage, preventing the progression to cirrhosis and hepatocellular 
carcinoma. Parameters of response to treatment to be considered are: 1) seroconversion of 
HBeAg to anti-HBe, 2) disappearance of HBV DNA from serum, 3) normalization of ALT 
level, and 4) improvement of liver histology. Two therapeutic approaches have been used in 
the treatment of HBV chronic infections: immune modulators and antiviral agents in the 
form of analogues of nucleos(t)ides. In the first category, conventional or pegylated 
interferon alpha (IFN-) is the unique option. Approximately 20% of HBeAg positive 
patients treated with IFN seroconverted to anti-HBe (Karayiannis, 2004). Treatment with 
IFN has advantages such as a short duration (six months to one year) of treatment, absence 
of antiviral resistance and excellent quality and duration of response. Its disadvantages are 
mainly the side effects such as flu-like symptoms and hematologic, neuropsychiatric, 
dermatological, endocrine, respiratory, ophthalmic and cardiovascular reactions (Fattovich 
et al., 1996). The second class of antiviral agents for the treatment of chronic hepatitis B is the 
analogs of nucleos(t)ides. Today five drugs, lamivudine, adefovir dipivoxil, entecavir, 
telbivudine, and tenofovir  have been approved in many parts of the world (Dienstag, 2008). 
These agents inhibit reverse transcription of the HBV polymerase and are well tolerated. 
However the occurrence of drug resistant viral isolates has been the main factor limiting the 
effectiveness of these drugs. These analogs of nucleos(t)ides are also used as part of the 
highly active antiretroviral therapy to treat HIV infection. HBV clinical trials and concurrent 
improvements in diagnostic technology may ensure that treatment options and expert 
opinion on patient management will continue to evolve. HBV genotyping and phenotyping 
of resistant isolates helps to delineate patterns of resistance and cross-resistance. These data 
may help to maximize the benefits of antiviral agents and improve the design of new 
therapeutic strategies (Zoulim&Locarnini, 2009). 
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10. Geographic distribution of HBV genotypes in the general population 
HBV is a unique enveloped double-stranded DNA virus that employs the error-prone 
polymerase reverse transcriptase as part of its replication process. This has resulted in a 
large genetic variability over the years of virus evolution within its hosts. Based on sequence 
divergence in the entire genome of 8% or more, HBV isolates are classified into eight 
genotypes, designated A to H, with a distinct geographical distribution (Arauz-Ruiz et al., 
2002; Norder et al., 2004; Norder et al., 1994; Stuyver et al., 2000).  Genotype A circulates in 
Europe, India, Africa, and North and South Americas. Isolates belonging to genotypes B and 
C have been observed in Southeast Asia and the Far East. Genotype D is widespread, with a 
high prevalence in the Mediterranean area and in the Middle East region. Genotype G is 
infrequent and has mainly been found in Europe, Mexico, and USA, while genotype E is 
native from West Africa and genotypes F and H are considered indigenous to Latin America 
(Figure 3). Recently, two novel genotypes, I and J, the former described in Laos and Vietnam 
(Olinger et al., 2008; Tran et al., 2008), and the latter in Japan (Tatematsu et al., 2009), have 
been proposed, but their designation as new genotypes is still controversial. There is a great 
deal of diversity within the genotypes and this has led to the division of some genotypes 
into different subgenotypes, such as A1–A6 in HBV of genotype A (HBV/A), B1–B8 in 
HBV/B, C1–C10 in HBV/C, D1–D7 in HBV/D, and F1-F4 in HBV/F (Huy et al., 2006; 
Kramvis et al., 2008; Lusida et al., 2008; Meldal et al., 2009; Mulyanto et al., 2009; Norder et 
al., 2004; Nurainy et al., 2008; Pourkarim et al., 2010; Sakamoto et al., 2006; Utsumi et al., 
2009; Wang et al., 2007). 
 
 
Fig. 3. Worldwide distribution of HBV genotypes. Adapted from 
<http://web.ucsf.edu/sfhbc/elective/2005/fall/Virology_Bass.ppt> [Date of access: 21 
June 2008]. 
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11. HBV and hemodialysis 
It is well known that hemodialysis patients are at high risk of acquiring parenterally 
transmitted infections, not only because of the large number of blood transfusions that they 
receive, and the invasive procedures that they undergo, but also because of their 
immunosuppressed state. The prevalence of HBV infection in patients on maintenance 
hemodialysis is usually higher compared with rates from the general population. Recent 
data from Mexico showed that prevalence of HBV infection in patients on maintenance 
hemodialysis was about 7%, 35 times higher than in the general population (Paniagua et al., 
2010). In dialysis units both patient-to-patient and patient-to-staff transmission of HBV have 
been recognized since the 1960s. Controlling the spread of HBV infection in dialysis units 
has been a major advance in the management of patients with chronic kidney diseases. 
Before the advent of vaccination, some success in limiting the spread of HBV was achieved 
by dialysing seropositive patients separately from those who were seronegative. This 
followed the publication in the UK of the Rosenheim Report in 1972 
(RosenheimAdvisoryGroup, 1972), which set out a code of practice for reducing 
transmission of hepatitis among dialysis patients. Before adoption of the universal infection 
control practices and HBV vaccination, high prevalence rates of HBV serological markers 
were found in hemodialysis patients globally. In addition to epidemiologic issues, 
management of HBV infection in dialysis population has evolved because of advances in 
antiviral therapy and improvements in diagnostic techniques (Fabrizi et al., 2008).  
The rate of de novo HBV infection in patients undergoing regular hemodialysis in the 
developed world is currently low (Finelli et al., 2005). In developed countries, where the 
infection control procedures have been implemented, HBV infection declined significantly, 
reaching HBsAg rates lower than 1.0% (Alter et al., 1986; Tokars et al., 2002). However, 
outbreaks of HBV infection continue to be reported occasionally in dialysis units in the 
developed world with some cases of fulminating hepatitis and even death (Inoue et al., 2006; 
Kondili et al., 2006). In the less-developed world, where the hemodialysis infection control 
practices and hepatitis B vaccination have been implemented lately, there are reports with 
rates of chronic HBsAg carriers ranging between 2% and 20% (Boulaajaj et al., 2005; Busek et 
al., 2002; Chattopadhyay et al., 2005; Covic et al., 1999; Fabrizi et al., 2008; Teles et al., 2002; 
Vladutiu et al., 2000). The higher HBV infection rates within dialysis units in the developing 
world can be attributed to several factors, an important one being the higher background 
prevalence of HBV in the general population. Also playing a prominent role are difficulties 
following infection control strategies against HBV such as, routine hemodialysis 
precautions, separating HBsAg-positive patients by rooms, machines, and staff, vaccination 
against HBV, and blood screening, attributable, at least in part, to a lack of financial and 
other resources (CDC, 2001). 
12. Occult HBV infection in hemodialysis patients  
HBsAg is the established serological marker for the diagnosis of acute or chronic HBV 
infection, and the absence of HBsAg in serum has been used as a surrogate marker for the 
absence of DNA and active viral replication. However, the development of highly sensitive 
molecular biology techniques has allowed detection of low levels of HBV DNA in the serum 
and/or liver of patients without detectable HBsAg (Coursaget et al., 1991; Gomes et al., 
1996; Hu, 2002; Jeantet et al., 2002). This peculiar form of chronic viral infection has been 
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termed occult HBV infection (Hu, 2002; Raimondo et al., 2007; Torbenson&Thomas, 2002). 
Individuals with occult HBV infection usually have serological evidence of previous 
exposure to the virus, mainly antibodies to core antigen (anti-HBc), although the absence of 
any serological marker related to HBV has also been described (Villa et al., 1995). Several 
possible explanations for HBV DNA persistence in the absence of HBsAg have been 
proposed. Low rate of HBV replication due to host’s immune response or co-infection with 
other infectious agents may account for occult status in the majority of the cases (Raimondo 
et al., 2007). However, occult HBV infection may also be due to mutations that inhibit 
HBsAg expression (Chaudhuri et al., 2004) or change HBsAg antigenicity, thus preventing 
detection by commercial assays (Araujo et al., 2008; Carman et al., 1997; Jeantet et al., 2004; 
Yamamoto et al., 1994).  
The prevalence of occult HBV infection is variable in different populations and depends on 
the general prevalence of HBV (Allain, 2004; Hu, 2002). The apparent prevalence also 
depends on the relative sensitivity of HBsAg and HBV DNA assays (Brechot et al., 2001; 
Conjeevaram&Lok, 2001). Occult HBV infection has been documented in a variety of clinical 
situations, most commonly among patients with hepatitis C virus (HCV) infection, in which 
the highest prevalence of occult HBV has been observed, especially in those who are 
positive for anti-HBc (Chemin&Trepo, 2005; Torbenson&Thomas, 2002). It is now 
established that occult HBV infection among non-HCV patients suffering from chronic 
hepatitis ranges from 20–30% in Europe and, in the context of HCV infection, ranges from 
20% in France to 80% in Japan (Chemin&Trepo, 2005). Individuals at high risk of 
parenterally transmitted infections also have a high prevalence of occult HBV infection. 
Therefore, hemodialysis patients are at increased risk of occult HBV infection. Parenteral 
exposure also favors contamination by HCV (Dai et al., 2001).  
The studies performed up to now on hemodialysis patients provide widely divergent 
results, reporting a prevalence of occult HBV that ranges from 0% to 36% (Besisik et al., 
2003; Fabrizi et al., 2005; Goral et al., 2006; Kanbay et al., 2006; Minuk et al., 2004; Motta et 
al., 2010; Siagris et al., 2006). These apparent discrepancies may be explained by significant 
differences in the prevalence of HBV infection in different geographic regions and/or by the 
detection limits of different HBV-DNA assays. In this context, it is of note that several 
authors consider occult HBV as a possible source of virus spread in hemodialysis units, thus 
representing a risk of infection for both patients and staff, and suggest some precautions 
including HBV DNA screening for all hemodialysis patients (Minuk et al., 2004). 
13. HBV variants in the general population vs. among hemodialysis patients  
In this topic, we will discuss the flow of contamination of different HBV genotypes in 
hemodialysis centers. We will address the circulation of HBV variants in the general 
population and among hemodialysis patients. Are some genotypes more disseminated in 
the hemodialysis environment? How to trace nosocomial transmission? 
HBV itself is not a directly cytotoxic virus. Instead, it destroys liver cells indirectly by 
stimulating the immune response. When the body fails to produce a sufficiently vigorous 
immune response to HBV during initial infection, chronic infection develops. This persistent 
but ineffective response results in progressive liver damage and fibrosis (Lindh et al., 1999). 
Although the host’s immune response to HBV infection determines the extent of liver injury, 
evidence of an association between HBV genotypes and clinical outcomes, activity of liver 
disease, HBV replication, and treatment responses, is growing (Chu&Lok, 2002; Kao, 2002; 
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Mayerat et al., 1999; McMahon, 2009; Schaefer, 2005). An association between genotype A 
and a chronic outcome of HBV infection has been proposed (Mayerat et al., 1999; Ozasa et 
al., 2006). It has been demonstrated that the replication capacity of HBV in transfected 
hepatoma cells varied among HBV genotypes, with genotype A having the lowest 
replication capacity (Sugiyama et al., 2006). Therefore, it is probable that the propensity of 
HBV genotype A infections to lead to chronicity would be due to less intensive immune 
responses because of its slow viral dynamics (Ozasa et al., 2006). In addition, the analysis of 
the level of cellular stress induced by transfection with distinct HBV genotypes revealed that 
the lowest level was achieved with genotype A (Sugiyama et al., 2006). On the other hand, 
the majority of cross-sectional and prospective studies show that individuals infected with 
HBV genotype C have an increased and earlier risk of liver inflammation, liver fibrosis, 
cirrhosis and liver cancer than those infected with other genotypes, including genotype B 
that co-exists in the same geographic area, suggesting that genotype C may be the most 
virulent of the HBV genotypes (Chan et al., 2004; Chen et al., 2004; Kao, 2002). People 
infected with HBV genotype C clearly have higher levels of HBV DNA, as evidenced by 
prolonged HBeAg positivity, than those infected with other genotypes. As a result, they 
experience prolonged viremia throughout much of their lives, giving more time for HBV 
integration to occur and more opportunity for liver inflammation and fibrosis. Additionally, 
certain mutations such as the basal core promoter mutation, that independently may be 
associated with a higher risk of liver cancer, appear to occur more frequently in those 
infected with genotype C (McMahon, 2009).  
Antiviral resistance to nucleos(t)ides analogs used for hepatitis B treatment has been 
associated with the genetic variability of HBV (Kramvis&Kew, 2005; Liu&Kao, 2008; 
Wiegand et al., 2008). Among the five nucleos(t)ides analogs  licensed for treatment (see 
Topic 9), primary resistance mutations have been identified for lamivudine (Allen et al., 
1998), telbivudine (Yang et al., 2005), entecavir (Colonno et al., 2006) and adefovir (Angus et 
al., 2003). Only tenofovir is not certain to cause resistance. All drug resistant mutations are 
confined to eight (169, 180, 181, 184, 202, 204, 236 and 250) aminoacid positions of the 
reverse transcriptase domain of pol gene (Locarnini, 2008). Lamivudine, also known as 3TC, 
was the first nucleoside analog to be licensed by the FDA for use in the treatment of chronic 
HBV infection in 1998 (Karayiannis, 2004). Primary lamivudine resistance associated 
changes result in amino acid changes within the tyrosine-methionine-aspartate-aspartate 
(YMDD) motif - rtM204V/I (methionine to valine or isoleucine substitution at codon 204). 
These changes cause a greater than 100-fold decrease in susceptibility to lamivudine in 
phenotypic assays. The compensatory mutations associated with lamivudine resistance, 
rtV173L (valine to leucine substitution), and rtL180M (leucine to methionine substitution) 
restore replication fitness of HBV polymerase that harbors the rtM204V/I mutation (Ono et 
al., 2001). 
The genetic variability of HBV strains circulating in hemodialysis units has been an 
important matter of study worldwide. One of the most extensive studies of HBV 
contamination and nonequivalent, genotype-specific spread in hemodialysis centers was 
conducted in Goiania city, located at the Central-West region of Brazil (Teles et al., 2002). 
Brazil, a country with a highly miscegenated population, exhibits an HBV genotype 
circulation pattern that is distinct from the distribution found in other Latin American 
countries. In Brazil, genotypes A, D and F co-circulate. Of these, subgenotype A1, the 
African subgenotype of genotype A (Bowyer et al., 1997; Kramvis et al., 2002), is the most 
prevalent among Brazilian HBV carriers (Araujo et al., 2004; Mello et al., 2007). The 
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distribution of HBV genotypes A and D in Brazil exhibit a gradient from northern to 
southern regions, reflecting the influence of Caucasian, African, and native Indian 
populations. North, Northeast and Southeast regions show a higher prevalence of genotype 
A. The high rate of genotype D isolates in the South region could be related to the influx of 
immigrants from Central Europe (especially Germany and Italy) that occurred in that region 
at the beginning of the 20th century. The balanced distribution of genotypes A and D in the 
Central-West region could be explained by the delayed occupation of that area by 
population migration flows from South, Southeast and Northeast regions (Mello et al., 2007). 
According to the study of Teles and cols. (Teles et al., 2002), in 1995, HBsAg prevalence 
among hemodialysis patients was approximately 10%, and genotypes A (50%) and D 
(46.2%) were almost detected equally in hemodialysis units from Goiania city. A survey of 
hemodialysis units in this city from 1995 to 1999 indicated that all newly infected patients 
harbored genotype D. By 1999, this resulted in a shift to genotype D being the predominant 
genotype (65.5%) (Teles et al., 2002). These data suggest that genotype D would be more 
likely to disseminate in the hemodialysis environment. In fact, although genotype A is the 
most prevalent genotype in Brazil, HBV genotype D strains have been involved frequently 
in hepatitis B outbreaks in dialysis units (Castro-Figueiredo et al., 1986; De Castro et al., 
2000; Lewis-Ximenez et al., 2001; Roll et al., 1995), and in some of these cases they were 
probably more efficiently transmitted than genotype A (Castro-Figueiredo et al., 1986; De 
Castro et al., 2000; Teles et al., 2002). Additionally, several studies have shown a significant 
association of HBV genotype D and injection drug use (Fisker et al., 2004; Panessa et al., 
2009; Swenson et al., 2001), reinforcing the idea that genotype D could be a blood-borne 
genotype. Other studies focusing on the molecular analysis of HBV isolates have been 
reported a high prevalence of genotype H and genotype B among hemodialysis patients 
from Mexico (Alvarado-Esquivel et al., 2006) and Indonesia (Lusida et al., 2003), 
respectively.   
Nosocomial transmission in the dialysis setting has been reported as a result of reusing 
multi-dose vials, staff shortages and subsequent need to care simultaneously for HBV 
infected and uninfected individuals, and contamination of equipment and environmental 
surfaces (Wreghitt, 1999). To confirm a common source of infection, it is necessary to 
demonstrate that patients have been infected with the same strain of virus. A nosocomial 
transmission of hepatitis B genotype E in UK has been recently reported (Ramalingam et al., 
2007). In this study, it was likely that two independent transmission events occurred in the 
ward and/or in the theatre recovery area. Both patients 1 and 2 with acute hepatitis B, and 
patient 3, an anti-HBe positive carrier had genotype E infections. The phylogenetic analyses 
demonstrated that the HBV strain infecting the three patients were identical in both the 
surface and core regions (Ramalingam et al., 2007). De Castro and cols. investigated the 
genetic variability of HBV strains circulating in two hemodialysis units by RFLP analysis 
(De Castro et al., 2000). Comparison between RFLP patterns of HBV strains was thus used to 
assess the nosocomial spread of HBV infection in each hemodialysis center. In this study, 
viral isolates of 27 HBsAg positive hemodialysis patients and 39 HBV-positive unrelated 
control patients, were grouped according to their RFLP patterns. In hemodialysis unit A, 14 
HBV isolates were grouped into five different RFLP patterns: A1, A2 and A3 (for genotype 
A strains), and, D3 and D4 (for genotype D). Pattern A2, present at a relatively low 
prevalence (18%) in the control group, was observed in the majority (53%) of the 
hemodialysis patients. Notably, all five patients who seroconverted to HBsAg positivity in 
1995 carried the strain of RFLP pattern A2. In hemodialysis unit B, where an outbreak of 
www.intechopen.com
 
Hepatitis B Virus (HBV) Variants in Hemodialysis Patients 25 
HBV infection occurred in 1996–1997, RFLP analysis showed that all 13 patients who 
seroconverted to HBsAg were infected with HBV isolates of genotype D. Coinfection with 
strains of RFLP pattern A1 was detected in seven of them (De Castro et al., 2000). 
There are concerns about HBV variants detected in cases of occult infection, if they may be 
transmitted to other hemodialysis patients and whether or not they may cause liver disease. 
Interesting, two studies, one performed in Turkey (Besisik et al., 2003) and other in Brazil 
(Motta et al., 2010), reported high prevalence of lamivudine resistant mutations in a 
significant proportion of hemodialysis patients with occult HBV infection, who had not 
previously received lamivudine treatment. It has been demonstrated that rtM204V/I 
mutants have a markedly decreased replication phenotype compared with wild-type HBV 
(Melegari et al., 1998), whereas both rtV173L and rtL180M substitutions act as compensatory 
changes that partially restore the replication fitness of the virus (Delaney et al., 2003; Ono et 
al., 2001). The triple lamivudine resistance mutation causes the concomitant amino acid 
substitutions E164D and I195M in the HBsAg as a result of the overlapping reading frames 
of the envelope and polymerase genes (Locarnini, 1998). It has been shown that both E164D 
and I195M substitutions reduce in vitro affinity of HBsAg to anti-HBs antibodies, similar to 
the HBV vaccine escape mutant G145R (Torresi et al., 2002). The HBsAg Y100C substitution 
is also frequently found among occult HBV infection carriers. Y100C has been found in cases 
of occult HBV infection among Venezuelan blood donors (Gutierrez et al., 2004), individuals 
from an Afro-Brazilian community (Motta-Castro et al., 2008) and HIV-HBV co-infected 
patients (Araujo et al., 2008). Among hemodialysis patients with occult HBV infection, the 
Y100C mutation has been also frequently found (Motta et al., 2010). Due to these 
observations, the role of Y100C substitution in reducing 
amount of HBsAg or changing HBsAg affinity by commercial antibodies was recently 
investigated by Mello and cols. (Mello et al., 2011). This study compared the levels of HBsAg 
detected by ELISA after transfection assays using recombinant plasmids with or without 
Y100C substitution. The results indicated that Y100C substitution alone did not negatively 
affect the detection and/or secretion of HBsAg. However, further studies analyzing the 
complete genome of HBV strains with the Y100C substitution may elucidate whether this 
mutation affects HBV replication or if there are mutations in other HBV genomic region that 
could explain the association of these variants with occult hepatitis B infection (Mello et al., 
2011).  
14. Conclusions 
Hepatitis B remains a major health issue in dialysis patients. Despite the introduction of 
effective infection control measures to minimize patient-to-patient transmission, occasional 
outbreaks occur in dialysis units, usually because of lapses in practice. Although the 
importance of occult HBV infection in the pathogenesis of hepatic disease has not yet been 
established, an increase number of studies have indicated a need to survey this group of 
patients. Occult HBV infection has been frequently observed among hemodialysis patients 
and could be a source of viral spread within hemodialysis units, representing a risk of 
infection for both patients and staff. YMDD variants are a common accompaniment and 
require further investigations with regard to clinical implications, once lamivudine 
treatment of possible HBV relapse in these patients might be accompanied by fast-viral 
resistance formation. Therefore, further studies with genome sequencing may provide more 
detail information on the molecular epidemiology of HBV infection, which may be helpful 
in understanding the HBV transmission in the hemodialysis population. 
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